Tafsure 25 mg Tenofovir Alafenamide

Description

Tafsure 25 mg (Tenofovir alafenamide) is an oral tablet used in patients with Hepatitis B viral (HBV) and HIV-1 infections. The pro-drug is highly efficient in its activities even with 10 times lower dose than its predecessor (Tenofovir disoproxil). Tafsure 25 mg (Tenofovir alafenamide) is administered in the form of a 25 mg oral dosage with food. It is taken once daily in the morning or evening.

Tafsure 25 mg (Tenofovir alafenamide) is specifically indicated against compensated (with a functional system) liver disease in adults. Plus, in combination with other anti-HBV (anti-retroviral) drugs, it can be employed in treatment-naïve HIV-1 patients. However, Tafsure 25 mg (Tenofovir alafenamide) is not recommended in HBV patients with decompensated (without a functional system) liver disease. In terms of modifications, the dosage regimen remains the same even if the patients have kidney or other liver complications.

Tafsure 25 mg (Tenofovir alafenamide) once swallowed, takes around 48 minutes to absorb in the system and after reaching the site of infection, binds efficiently with viral cells. Once the anti-viral activities are completed, more than 50% of the drug is excreted from the body in roughly 51 minutes.